GlassScriptPhysician profile
Steven Neus
NPI 1801895396
$3,229.43
in general payments reported to CMS, 2019-2025
38 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.05 · 2020: $236 · 2021: $906 · 2022: $653 · 2023: $431 · 2024: $336 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.88 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $385.22 | 2021-2025 | |
| Abbvie INC. | $295.80 | 2021-2024 | |
| Novo Nordisk INC | $227.25 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $205.06 | 2020-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.11 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $193.71 | 2020-2025 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $178.49 | 2020-2023 | Austedo |
| Sanofi-Aventis U.S. LLC | $161.25 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.99 | 2019-2025 | Trintellix |
| Alkermes, INC. | $127.88 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Astrazeneca Pharmaceuticals LP | $110.15 | 2020-2025 | Farxiga, Breztri |
| Amgen INC. | $95.13 | 2019-2025 | Otezla, Repatha, Otezla |
| Gilead Sciences, INC. | $85.84 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $74.78 | 2022 | |
| Axsome Therapeutics, INC. | $70.47 | 2023-2025 | Auvelity |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Neus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.